|
 |
|
| |
|
Newsletter Sponsor
|
|
‘ONE AND DONE’ DAILY DOSING INVOLVING A HIGHLY WATER-SOLUBLE API - A Formulation Development Case Study
Metrics Contract Services was approached by a client with a clinical trial that would enroll patients for whom medication compliance would be extremely difficult. So the client requested an easy and palatable “one and done” daily dosing.
This meant the formulation required almost every deliverable a scientist can produce — uniform-sized multi-particulate for consistent controlled release; taste masking and small particle size to improve patient compliance; 24-hour modified release for once-a-day dosing; and dose dumping prevention.
Read the case study at metricsinc.com.
 |
|
|
|
|
|
|
|
|
|
 |
Featured Articles |
 |
|
| |
|
|
|
Trends Affecting CROs & CMOs in 2016 Look Positive
Trends Affecting CROs & CMOs in 2016 Look Positive
While CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is
getting a lot of attention as this year’s potential wonder therapy, the generics
industry continues to undergo change. ...
read more » |
 |
|
|
 |
| |
|
|
Featured Partners |
|
|
| |
|
|
|
Albany Molecular Research Inc.
Albany Molecular Research Inc.’s (AMRI) Active Pharmaceutical Ingredients (API) business supports the chemical development and cGMP manufacture of complex API, including controlled substances, steroids, hormones, sterile API, as well as potent and cytotoxic compounds and sterile API. read more » |
|
|
|
|
Featured Video |
|
|
| |
|
|
|
|
|
|
Interview with Federal Equipment at Interphex 2015
Interview with Federal Equipment at Interphex 2015
Federal Equipment CEO Larry Kadis discusses the purchase and use of used equipment in the pharmaceutical industry with Mike Auerbach, Editor-in-chief of Pharmaceutical Outsourcing, at Interphex 2015. ...
read more » |
|
|
|
 |
| |
|
|
Featured Whitepaper |
|
|
| |
Proactive Pharmacovigilance
Proactive Pharmacovigilance
Pharmacovigilance is entering uncharted territory requiring industry, regulators, health care providers, and patients to address multiple unknowns. ...
read more »
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
